
    
      An open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and
      antiviral activity of ABT-267 as monotherapy for 2 days, followed by ABT-267, ABT-450 with
      ritonavir (ABT-450/r) and ABT-333 plus ribavirin (RBV) combination therapy for 12 weeks in
      treatment-na√Øve, non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. The
      study included post-treatment follow-up for 48 weeks.
    
  